🇺🇸 IgPro20 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Meningitis Aseptic — 2 reports (18.18%)
2. Abdominal Pain — 1 report (9.09%)
3. Asthma — 1 report (9.09%)
4. Cyst — 1 report (9.09%)
5. Diarrhoea — 1 report (9.09%)
6. Drug Eruption — 1 report (9.09%)
7. Dystonia — 1 report (9.09%)
8. Encephalitis — 1 report (9.09%)
9. Fluid Intake Reduced — 1 report (9.09%)
10. Herpes Zoster Oticus — 1 report (9.09%)

Source database →

Frequently asked questions

Is IgPro20 approved in United States?

IgPro20 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for IgPro20 in United States?

CSL Behring is the originator. The local marketing authorisation holder may differ — check the official source linked above.